MichaelBukhaloMD

PubMed

• 33 citations
  A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis
  April W. Armstrong, Michael Bukhalo, Andrew Blauvelt
  American Journal of Clinical Dermatology. 2016-07-19
• 5 citations
  Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
  Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, Michael Bukhalo, Alim R Devani
  The British Journal of Dermatology. 2023-09-15
• 49 citations
  Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psorias...
  Mark Lebwohl, Stephen K. Tyring, Michael Bukhalo, Javier Alonso-Llamazares, Martin Olesen
  The Journal of Clinical and Aesthetic Dermatology. 2016-02-01

Journal Articles

• Clinical Study Results of Desoximetasone Spray, 025% in Moderate to Severe Psoriasis  
  Kircik L, Lebwohl M, Del Rosso J, Bagel J, Gold L, Weiss J, Journal of Drugs in Dermatology, 1/1/2013
• Calcipotriene Plus Betamethasone Dipropionate Topical Suspension for the Treatment of Mild to Moderate Psoriasis Vulgaris on the body: A Randomized, Double-blind, Vehi...  
  Menter A, Gold L, Bukhalo M, Grekin S, Kempers S, Boyce B, Ganslandt C, Villumsen J, Lenwohl M, Journal of Drugs in Dermatology, 1/1/2013
• Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratosis  
  Bukhalo M, The Journal of Clinical and Aesthetic Dermatology, 1/1/2009
• Photo Quiz: Red, Scaly Lesion on the Upper Eyelid  
  Altman J, Tonelli D, Bukhalo M, American Family Physician, 1/15/2007
• Role of clinical examination is screening for blunt cervical spine injury  
  Gonzales RP, Fried PO, Bukhalo M, Holevar MR, Journal of American College of Surgeons, 1/1/1999
• Join now to see all

Abstracts/Posters

• A Novel Aerosol Foam Formulation of Calcipotriene (Cal) 0.005% Plus Betamethasone Dipropionate (BD) 0.064% is More Efficacious Than Cal and BD Foam Alone in Treating P...
  Lebwohl M, Tyring S, Bukhalo M, Alonso-Llamazares J, Oleses M, Lowson D, Yamauchi P, 73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA, 1/20/2015
• A Phase 2 Study of Photodynamic Therapy (PDT) with Aminolevulinic Acid HCI (ALA) 20% Topical Solution + Blue Light vs ALA Topical Solution Vehicle + Blue Light Using S...
  Pariser D, McConnehey D, Matheson R, Kempers S, Guenthner S, Bukhalo M, 71st Annual Meeting of the American Academy of Dermatology, Miami Beach, FL, 1/1/2013
• Randomized, Parellel-Group, Double-Blind, Vehicle-Controlled, Multicenter Phase 3 Study of the Efficacy and Safety of PEP005 (ingenol mebutate) Gel, 0.015% in Patients...
  Lebwohl M, Melgaard A, Xu Z, 22nd World Congress of Dermatology, Seoul, Korea, 1/24/2011
• Multicenter, Randomized,Parallel-Group, Double-Blind, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of PEP005 (ingenol) Gel 0.05% in Patients W...
  Anderson L, Melgaard A, Xu Z, 22nd World Congress of Dermatology, Seoul, Korea, 1/24/2011
• Join now to see all

Lectures

• A Novel Aerosol Foam Formulation of Calcipotriene (Cal) 0.005% Plus Betamethasone Dipropionate (BD) 0.064% is More Efficacious Than Cal and BD Foam Alone in Treating P... 
  Kaua'I, HI - 1/1/2015
• Use of Light Sources for Acne Therapy 
  St. Thomas, VI - 1/1/2009
• New Trends in Acne Therapy 
  San Antonio, TX - 1/1/2006
• LCV induced by Glyburide 
  Washington, DC - 1/1/2001
• Herpes simplex neonatorum presenting in a zosteriform distribution 
  San Francisco, CA - 1/1/1997
• Join now to see all